The purpose of this study is: - To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. - To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. - To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. - To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).
Name: T3Description: Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.Type: Drug
There is one SNP
The DI-C785T allele will be associated with lower T3 levels at baseline and faster treatment response. --- C785T ---